Citations

Clear

3138 citation(s) found for "Smith, AM".

Impact of heart failure with preserved ejection fraction on large conducting airways in humans
Johnston, Jessica, Johnson, Bruce D. , Borlaug, Barry A. , Smith, Joshua R.

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5732981 Get It

Background: Heart failure patients with preserved ejection fraction (HFpEF) exhibit exercise intolerance and exertional dyspnea. The underlying pathophysiology is complex and involves multiple physiological systems. To this point, HFpEF patients exhibit pulmonary abnormalities at rest and during exercise. For example, HFpEF patients have higher work of breathing during exercise due to greater inspiratory and expiratory resistive work of breathing. Importantly, this greater resistive work of breathing is not associated with higher inspiratory and expiratory flow rates suggesting pulmonary resistance is elevated in HFpEF patients. One potential explanation for the increase in resistive work of breathing during exercise in HFpEF patients is smaller luminal area of the airways. Purpose: The purpose of this study was to determine if differences exist in the luminal area of the large conducting airways in HFpEF patients compared to controls. We hypothesized that HFpEF patients will exhibit smaller luminal areas of the large conducting airways compared to controls. Methods: HFpEF patients (n=9; 67±7 yrs; 30±3 kg/m2) and controls (n=8; 62±9 yrs; 24±3 kg/m2) were enrolled. All participants performed pulmonary function testing and a thoracic computerized tomographic (CT) scan (assessed at total lung capacity). The airway luminal area was quantified from three-dimensional reconstructions from the high-resolution CT scans. The luminal areas of the large conducting airways were measured at three discreet points (corresponding to the beginning, middle, and end of the airway), averaged, and indexed to height. Results: The luminal area of the trachea was not different between groups (p=0.95). HFpEF patients had smaller luminal area of the right main bronchus (control: 1.38±0.21 vs. HFpEF: 1.18±0.13 mm2/cm) and left main bronchus (control: 0.98±0.20 vs. HFpEF: 0.79±0.15 mm2/cm) (both, p<0.04) than controls. HFpEF patients also had smaller luminal area of the bronchus intermedius (control: 0.82±0.14 vs. HFpEF: 0.67±0.15 mm2/cm) and left lower lobe bronchus (control: 0.48±0.13 vs. HFpEF: 0.36±0.07 mm2/cm) compared to controls (both, p<0.04). No differences were present between groups in the right and left upper lobe bronchi (both, p>0.40). Conclusion: HFpEF patients have smaller luminal areas of some, but not all large conducting airways compared to controls. These findings provide support for smaller large conducting airways in HFpEF contributing to the pulmonary abnormalities during exercise in these patients. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Comparison of shear-wave elastography to state-of-the-art respiratory function testing to measure the range of forces generated by the diaphragm muscle
Knoll, Kate M , Lee, Hyungkyi, Johnson, Bruce D. , Gransee, Heather M. , Smith, Joshua R. , Johnston, Jessica, Jiang, Lai , Urban, Matthew W. , Mantilla, Carlos B.

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731374 Get It

The diaphragm muscle is important in both sustaining ventilation and performing higher-force behaviors necessary for maintaining airway patency. Ventilatory behaviors (i.e., eupnea and response to hypoxia-hypercapnia) require only ~20% of maximal force generation, whereas coughing requires forces ~60% of maximal. Existing techniques to measure the full range of forces generated by respiratory muscles are limited by their invasiveness (e.g., balloon manometry for transdiaphragmatic pressure (Pdi) measurements), requirements for training, supervision and subjectivity (e.g., maximal inspiratory and expiratory pressures). Ultrasound-based shear-wave elastography (SWE) assesses muscle stiffness and has shown promising results in being used as a surrogate for Pdi to evaluate diaphragm muscle force. Previous literature has demonstrated a correlation between diaphragm SWE and Pdi at lower force behaviors and the goal of the present study was to evaluate the efficacy of SWE-based measurements of the diaphragm in correlating with Pdi measurements across the range of forces generated by the diaphragm. In this pilot study, we recruited 6 male and 5 female healthy volunteers. Subjects were positioned in a seated position with their torso unsupported. Pdi was measured during graded inspiratory threshold loading trials using a POWERbreathe Plus commercial inspiratory loading device, as well as during maximal inspiratory pressure (MIP). Simultaneously, SWE was performed at the zone of apposition in the right anterior axillary line, and diaphragm Young’s modulus and shear wave speed were subsequently measured. The average Pdi during MIP testing was 149 ± 66 cm H2O. Pdi during inspiratory loading at a low resistance was 39 ± 14 cm H2O and at a high resistance was 78 ± 29 cm H2O. Subjects were able to generate an average Pdi range of 39 ± 19 cm H2O across the graded resistance levels, and the average percent of MIP obtained was 54 ± 13%. Average Young’s modulus as measured with SWE during inspiratory loading at a low resistance was 46 ± 19 kPa and at a high resistance was 104 ± 19 kPa. From low to high resistance, Pdi, Young’s modulus, and shear wave speed increased by an average of 100%, 126%, and 59%, respectively. Taken together, SWE is a promising method of non-invasive assessment of diaphragm muscle forces across a range of voluntary behaviors. Support from NIH grant R21 DA055848 and the Mayo Clinic. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Pulmonary Pathology Society Survey on Practice Approaches in the Histologic Diagnosis of Fibrotic Interstitial Lung Disease: Consensus and Opportunities
Butterfield, Richard , Đačić, Sanja , Colby, Thomas V. , Beasley, Mary Beth , Smith, Maxwell L. , Mino-Kenudson, Mari A. , Churg, Andrew , Hariri, Lida P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | May 25, 2023 | Volume: 148 | Issue: 2 | Pages: 168-177

10.5858/arpa.2022-0530-oa | PMID 37226833 Get It

Context.— The pathologic diagnosis of usual interstitial pneumonia (UIP) remains a challenging area, and application of histologic UIP guidelines has proved difficult. Objective.— To understand current practice approaches by pulmonary pathologists for the histologic diagnosis of UIP and other fibrotic interstitial lung diseases (ILDs). Design.— The Pulmonary Pathology Society (PPS) ILD Working Group developed and sent a 5-part survey on fibrotic ILD electronically to the PPS membership. Results.— One hundred sixty-one completed surveys were analyzed. Of the respondents, 89% reported using published histologic features in clinical guidelines for idiopathic pulmonary fibrosis (IPF) in their pathologic diagnosis; however, there was variability in reporting terminology, quantity and quality of histologic features, and the use of guideline categorization. Respondents were very likely to have access to pulmonary pathology colleagues (79%), pulmonologists (98%), and radiologists (94%) to discuss cases. Half of respondents reported they may alter their pathologic diagnosis based on additional clinical and radiologic history if it is pertinent. Airway-centered fibrosis, granulomas, and types of inflammatory infiltrates were considered important, but there was poor agreement on how these features are defined. Conclusions.— There is significant consensus among the PPS membership on the importance of histologic guidelines/features of UIP. There are unmet needs for (1) consensus and standardization of diagnostic terminology and incorporation of recommended histopathologic categories from the clinical IPF guidelines into pathology reports, (2) agreement on how to incorporate into the report relevant clinical and radiographic information, and (3) defining the quantity and quality of features needed to suggest alternative diagnoses.
Rare variants in ANO1 , encoding a calcium-activated chloride channel, predispose to moyamoya disease
Pinard, Amélie , Ye, Wenlei , Fraser, Stuart , Rosenfeld, Jill A. , Pichurin, Pavel N. , Hickey, Scott E. , Guo, Dongchuan , Cecchi, Alana C. , Boerio, Maura L. , Guey, Stéphanie , Aloui, Chaker , Alyemni, Saleh, Bamshad, Michael J. , Nickerson, Deborah A. , Jin, Sheng Chih , Smith, Edward R. , Haider, Shozeb , Jin, Sheng Chih , Milewicz, Dianna M , Rosenfield, Jill A , Guey, Stéphanie , Smith, Edward , Lee, Kwanghyuk , Kraemer, Markus , Tournier‐Lasserve, Elisabeth , Haider, Shozeb , Kahle, Kristopher T. , Jan, Lily Yeh , He, Mu , Milewicz, Dianna M.

Mayo Clinic

Brain | May 24, 2023 | Volume: 146 | Issue: 9 | Pages: 3616-3623

10.1093/brain/awad172 | PMID 37253099 Get It

Abstract Moyamoya disease, a cerebrovascular disease leading to strokes in children and young adults, is characterized by progressive occlusion of the distal internal carotid arteries and the formation of collateral vessels. Altered genes play a prominent role in the aetiology of moyamoya disease, but a causative gene is not identified in the majority of cases. Exome sequencing data from 151 individuals from 84 unsolved families were analysed to identify further genes for moyamoya disease, then candidate genes assessed in additional cases (150 probands). Two families had the same rare variant in ANO1, which encodes a calcium-activated chloride channel, anoctamin-1. Haplotype analyses found the families were related, and ANO1 p.Met658Val segregated with moyamoya disease in the family with an LOD score of 3.3. Six additional ANO1 rare variants were identified in moyamoya disease families. The ANO1 rare variants were assessed using patch-clamp recordings, and the majority of variants, including ANO1 p.Met658Val, displayed increased sensitivity to intracellular Ca2+. Patients harbouring these gain-of-function ANO1 variants had classic features of moyamoya disease, but also had aneurysm, stenosis and/or occlusion in the posterior circulation. Our studies support that ANO1 gain-of-function pathogenic variants predispose to moyamoya disease and are associated with unique involvement of the posterior circulation.
Evaluation of advanced imaging biomarkers at kidney failure in patients with ADPKD: a pilot study
Wigerinck, Stijn , Gregory, Adriana , Iliuta, Ioan-Andrei, Hanna, Christian , Chedid, Maroun , Kaidbay, Hasan-Daniel N., Senum, Sarah R. , Shukoor, Shebaz, Harris, Peter C. , Kline, Timothy L. , Gregory, Adriana V, Harris, Peter C , Hanna, Christian , Senum, Sarah R , Smith, Byron H. , Torres, Vicente E. , Chebib, Fouad T.

Mayo Clinic

Clinical Kidney Journal | May 24, 2023 | Volume: 16 | Issue: 10 | Pages: 1691-1700

10.1093/ckj/sfad114 | PMID 37779848 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) presents with variable disease severity and progression. Advanced imaging biomarkers may provide insights into cystic and non-cystic processes leading to kidney failure in different age groups. Methods This pilot study included 39 ADPKD patients with kidney failure, stratified into three age groups (&lt;46, 46–56, &gt;56 years old). Advanced imaging biomarkers were assessed using an automated instance cyst segmentation tool. The biomarkers were compared with an age- and sex-matched ADPKD cohort in early chronic kidney disease (CKD). Results Ht-total parenchymal volume correlated negatively with age at kidney failure. The median Ht-total parenchymal volume was significantly lower in patients older than 56 years. Cystic burden was significantly higher at time of kidney failure, especially in patients who reached it before age 46 years. The cyst index at kidney failure was comparable across age groups and Mayo Imaging Classes. Advanced imaging biomarkers showed higher correlation with Ht-total kidney volume in early CKD than at kidney failure. Cyst index and parenchymal index were relatively stable over 5 years prior to kidney failure, whereas Ht-total cyst volume and cyst parenchymal surface area increased significantly. Conclusion Age-related differences in advanced imaging biomarkers suggest variable pathophysiological mechanisms in ADPKD patients with kidney failure. Further studies are needed to validate the utility of these biomarkers in predicting disease progression and guiding treatment strategies.
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Oni‐Orisan, Akinyemi , Tuteja, Sony , Hoffecker, Glenda , Smith, D. Max , Castrichini, Matteo , Crews, Kristine R. , Murphy, William A. , Nguyen, Nam , Huang, Yimei , Lteif, Christelle , Tantisira, Kelan G. , Cavallari, Larisa H. , Whirl‐Carrillo, Michelle , Duarte, Julio D. , Luzum, Jasmine A. , Nguyen, Nam H K , Friede, Kevin A , Aminkeng, Folefac , Voora, Deepak , Cavallari, Larisa H , Whirl-Carrillo, Michelle , Duarte, Julio D , Luzum, Jasmine A , Crews, Kristine R , Smith, D Max , Castrichini, Matteo , Oni-Orisan, Akinyemi , Murphy, William A.

Mayo Clinic

Clinical Pharmacology & Therapeutics | May 24, 2023 | Volume: 114 | Issue: 2 | Pages: 275-287

10.1002/cpt.2957 | PMID 37303270 Get It

Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
Letson, Christopher T. , Newman, Hannah , Binder, Moritz , Vedder, Alexis , Kinose, Fumi , Ball, Markus , Kruer, Traci , Quintana, Ariel , Lasho, Terra L. , Finke, Christy M. , Almada, Luciana L. , Grants, Jennifer M. , Zhang, Guolin , Fernández-Zapico, Martín E. , Gaspar‐Maia, Alexandre , Haura, Eric B. , Sallman, David A. , Reuther, Gary W. , Rix, Uwe , Patnaik, Mrinal M. , Padron, Eric , Balasis, Maria , Newman, Hannah , Binder, Moritz , Vedder, Alexis , Kinose, Fumi , Ball, Markus , Kruer, Traci , Quintana, Ariel , Lasho, Terra L , Finke, Christy M , Almada, Luciana L , Grants, Jennifer M , Zhang, Guolin , Fernandez-Zapico, Martin E , Gaspar-Maia, Alexandre , Lancet, Jeffrey E , Komrokji, Rami S , Haura, Eric , Sallman, David A , Reuther, Gary W , Karsan, Aly , Rix, Uwe , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lancet, Jeffrey E. , Komrokji, Rami S.

Mayo Clinic

Clinical Cancer Research | May 24, 2023 | Volume: 29 | Issue: 15 | Pages: 2919-2932

10.1158/1078-0432.ccr-22-3929 | PMID 37223910 Get It

Abstract Purpose: Preclinical studies in myeloid neoplasms have demonstrated efficacy of bromodomain and extra-terminal protein inhibitors (BETi). However, BETi demonstrates poor single-agent activity in clinical trials. Several studies suggest that combination with other anticancer inhibitors may enhance the efficacy of BETi. Experimental Design: To nominate BETi combination therapies for myeloid neoplasms, we used a chemical screen with therapies currently in clinical cancer development and validated this screen using a panel of myeloid cell line, heterotopic cell line models, and patient-derived xenograft models of disease. We used standard protein and RNA assays to determine the mechanism responsible for synergy in our disease models. Results: We identified PIM inhibitors (PIMi) as therapeutically synergistic with BETi in myeloid leukemia models. Mechanistically, we show that PIM kinase is increased after BETi treatment, and that PIM kinase upregulation is sufficient to induce persistence to BETi and sensitize cells to PIMi. Furthermore, we demonstrate that miR-33a downregulation is the underlying mechanism driving PIM1 upregulation. We also show that GM-CSF hypersensitivity, a hallmark of chronic myelomonocytic leukemia (CMML), represents a molecular signature for sensitivity to combination therapy. Conclusions: Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data support further clinical investigation of this combination.
Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
Degnim, Amy C. , Siontis, Brittany L. , Ahmed, Safia K. , Hoskin, Tanya L. , Hieken, Tina J. , Jakub, James W. , Baum, Christian L. , Day, Courtney N. , Schrup, Sarah E. , Smith, Lauren , Carter, Jodi M. , Sae-Kho, Tiffany M. , Glazebrook, Katrina N. , Vijayasekaran, Aparna , Okuno, Scott H. , Petersen, Ivy A. , Day, Courtney , Siontis, Brittany L , Hieken, Tina J , Degnim, Amy C , Jakub, James W , Hoskin, Tanya , Carter, Jodi

Mayo Clinic

Clinical Cancer Research | May 24, 2023 | Volume: 29 | Issue: 15 | Pages: 2885-2893

10.1158/1078-0432.ccr-23-0443 | PMID 37223927 Get It

Abstract Purpose: To evaluate the impact of trimodality treatment versus monotherapy or dual therapy for radiation-associated angiosarcoma of the breast (RAASB) after prior breast cancer treatment. Experimental Design: With Institutional Review Board approval, we identified patients diagnosed with RAASB and abstracted data on disease presentation, treatment, and oncologic outcomes. Trimodality therapy included (i) taxane induction, (ii) concurrent taxane/radiation, and then (iii) surgical resection with wide margins. Results: A total of 38 patients (median age 69 years) met inclusion criteria. Sixteen received trimodality therapy and 22 monotherapy/dual therapy. Skin involvement and disease extent were similar in both groups. All trimodality patients required reconstructive procedures for wound closure/coverage, compared with 48% of monotherapy/dual therapy patients (P &lt; 0.001). Twelve of 16 (75%) patients receiving trimodality therapy had a pathologic complete response (pCR). With median follow-up of 5.6 years, none had local recurrence, 1 patient (6%) had distant recurrence, and no patients died. Among 22 patients in the monotherapy/dual therapy group, 10 (45%) had local recurrence, 8 (36%) had distant recurrence, and 7 (32%) died of disease. Trimodality therapy demonstrated significantly better 5-year recurrence-free survival [RFS; 93.8% vs. 42.9%; P = 0.004; HR, 7.6 (95% confidence interval, CI: 1.3–44.2)]. Combining all patients with RAASB regardless of treatment, local recurrence was associated with subsequent distant recurrence (HR, 9.0; P = 0.002); distant recurrence developed in 3 of 28 (11%) patients without local recurrence compared with 6 of 10 (60%) with local recurrence. The trimodality group had more surgical complications that required reoperation or prolonged healing. Conclusions: Trimodality therapy for RAASB was more toxic but is promising, with a high rate of pCR, durable local control, and improved RFS.
Cardiac rehabilitation participation and risk of falls in older individuals with cardiovascular disease
Chacin-Suarez, A, Zhang, Li , Taylor, Jennifer L. , Manemann, Sheila M., Bonikowske, Amanda R. , Squires, Ray W. , Salazar, J A Brenes, Terzic, Carmen M., Medina‐Inojosa, José R. , Fischer, Karen M. , Gomes, P F, Smith, Joshua R. , Salazar, Jorge Brenes, Thomas, Randal J.

Mayo Clinic

European Journal of Preventive Cardiology | May 24, 2023 | Volume: 30 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwad125.085 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background Falls are the leading cause of injury-related morbidity and mortality among older adults in the United States, including those with cardiovascular disease. Cardiac rehabilitation (CR) helps to optimize functional capacity, strength, and balance in patients with cardiovascular disease and, in theory, may reduce the risk of falls. However, little evidence has been published in this regard. Purpose The purpose of this study was to assess the association between CR participation and risk of falls in a community-based sample of individuals 65 years of age and older with cardiovascular disease who were eligible for CR participation. Methods Individuals from Southeastern MN and Western WI, USA, 65 years of age and older who had experienced a cardiovascular event that qualified them for CR (MI, PCI, CABG, Valve Surgery, Transplant) between January 1, 2000, and December 31, 2018, were included in this study. Participation in CR (≥1 sessions, CR-group) and subsequent falls (moderate or severe, using the Campbell classification system) were ascertained using the Rochester Epidemiology Project records-linkage system. Logistic model to create propensity weighting were used to test the association between CR participation and falls after adjustment for potentially confounding factors. Results A total of 5004 individuals met inclusion criteria for the study, with 2183 (44%) included in the CR group and 2821 (56%) in the non-CR group (CR was indicated, but the individual did not participate). Overall, 1122 patients experienced a fall within the first 5 years (16% of those in the CR-group, 23% of those in the non-CR group). After adjustment, CR participation was not associated with falls, but older individuals, females, and those with a history of falls were more likely to have had a fall, compared to young individuals, males, and those without a history of a fall. Conclusions While CR is beneficial for patients with cardiovascular disease, our study did not find evidence of an association between CR participation and fall risk in individuals 65 years of age and older who have cardiovascular disease. Additional research is needed to evaluate the role of CR components that may potentially reduce modifiable risk factors for falls and thereby reduce the risk of falls.
Adherence to cardiac rehabilitation: prevalence, barriers, predictors and potential solutions
Pola, Marta Supervía, Jarreta, Begona Martinez, Squires, Ray W. , Terzic, Carmen M., Medina‐Inojosa, José R. , Smith, Joshua R. , Leth, Steffen , López-Jiménez, Francisco , Thomas, Randal J.

Mayo Clinic

European Journal of Preventive Cardiology | May 24, 2023 | Volume: 30 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwad125.024 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background Cardiac rehabilitation (CR) is a key component in the continuum of care for patients with CVD that reduces mortality, morbidity and rehospitalization. Clinical practice guidelines strongly recommend and encourage CR participation for eligible patients with CVD. Although there are multiple studies on barriers and solutions to improve the initiation rates of CR, a limited number of studies have explored the barriers and solutions to increase the degree of adherence to CR. Purpose The aim of this study was to define those characteristics that predict adherence to CR with special focus on women and employed patients, since these groups are generally understudied. Methods We performed a retrospective electronic medical record review of the Mayo Clinic CR program, Rochester to identify patients who had started the Mayo Clinic program between January 1, 2014 and September 30, 2015. Among patients who met the inclusion criteria, we conducted a telephone survey with the aim of defining barriers to participation and possible solutions proposed by patients to increase CR adherence. The survey included factors previously identified in the literature as possible barriers, as well as other hypothetical factors; including closed and open-ended questions. The study was approved by the Mayo Clinic institutional review board. Results 376 patients met the inclusion criteria. 257 patients completed the survey. 240 (63.8%) returned the HIPAA (Health Information Use Authorization) document. 72 (30%) were women with a mean age of 66.4 ±12.4 years. Forty-seven percent (n = 113) of the participants did not complete the recommended course of 36 sessions of CR. Among the most important barriers, we found that schedule conflicts were more frequently noted to be a barrier to CR participation among employed patients compared to non-employed patients (p=0.04). Lack of motivation and an inadequate awareness of the importance of completing CR were significantly reported as barriers from employed and non-employed patients. Among the proposed solutions, the participants suggested the potential benefit of alternative delivery models for CR programs; as well efforts to improve awareness of the importance of CR adherence among patients and professionals. Conclusions This study has great relevance because it addressed barriers and potential solutions to CR adherence. Barriers such as mental stress and motivation, as well as a lack of knowledge about CR benefits highlight the role of patient counseling and education as keys to help improve CR adherence. Alternative CR delivery models are attractive options to help facilitate participation, with special focus on the employed population and women, as they more frequently report logistical barriers to CR compared to non-employed patients and men. Further research and advocacy work are needed to help identify and implement strategies that address barriers to CR adherence and completion.